As a portfolio company of Sumitomo Corporation, a global international trading company, Oxford offers unparalleled access to the Japanese marketplace. We introduce our clients to Sumitomo resources that will assist with
- Drug and diagnostics licensing
- Research and development collaborations for pharmaceuticals and medical devices
- Equity investments
Sumitomo Corporation
With assets exceeding $70 billion and offices in 66 countries, Sumitomo Corporation is one of Japan's leading traders and distributors of commodities, industrial products and consumer goods. In addition to being a channel for pharmaceuticals and medical device alliances, Sumitomo makes direct equity investments in emerging companies.
www.sumitomocorp.co.jp/english/Summit Pharmaceuticals International
Summit Pharmaceuticals, a Sumitomo Corporation subsidiary, facilitates strategic and commercial relationships between U.S. and Japanese life sciences companies, arranging licensing, production, and import and export of new drugs and diagnostic products. Summit Pharmaceuticals produces chemicals and compounds required to manufacture drugs, as well as manufacture finished biologic products. They also invest in select mid- to late-stage pharmaceutical companies. With more than 60 clients in Japan, Summit Pharmaceuticals' major accounts include Bristol-Myers Squibb, Abbott Laboratories, GlaxoSmithKline, Johnson & Johnson and Pfizer.
www.summitpharma.co.jp/english/
